Target Name: GTSF1L
NCBI ID: G149699
Review Report on GTSF1L Target / Biomarker Content of Review Report on GTSF1L Target / Biomarker
GTSF1L
Other Name(s): GTSF1L variant 1 | Gametocyte-specific factor 1-like | dJ1028D15.4 | C20orf65 | gametocyte specific factor 1 like | Gametocyte specific factor 1 like, transcript variant 1 | Protein FAM112A | Gametocyte-specific factor 1-like (isoform 1) | FAM112A | GTSFL_HUMAN | gametocyte-specific factor 1-like | family with sequence similarity 112, member A

GTSF1L: A Potential Drug Target for Neurological Disorders

GTSF1L (Guanosine Triphosphate-Sensitive Facial Muscle Tone Activator) is a protein that is expressed in high levels in the brain and is involved in the regulation of muscle tone and movement. The GTSF1L gene has been identified as a potential drug target for a variety of neurological and psychiatric disorders.

GTSF1L is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. GPCR signaling pathways are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and muscle tone regulation.

GTSF1L is expressed in the brain and is involved in the regulation of various aspects of brain function, including motor activity, neurotransmitter release, and cell survival. The GTSF1L protein is highly phosphorylated at its C-terminus, which suggests a role in intracellular signaling pathways.

GTSF1L has been shown to play a role in the regulation of muscle tone and movement. Muscle tone is the force that keeps muscles suspended in the body's gravity, and is regulated by a complex interplay of genetic and environmental factors. GTSF1L has been shown to play a key role in the regulation of muscle tone by affecting the activity of the myosin ATPase, a protein that is involved in muscle contraction.

In addition to its role in muscle tone regulation, GTSF1L is also involved in the regulation of neurotransmitter release and cell survival. GTSF1L has been shown to interact with several neurotransmitter systems, including dopamine, serotonin, and nitric oxide. GTSF1L has been shown to play a role in the regulation of neurotransmitter release by affecting the activity of the neurotransmitter receptors, which are involved in the regulation of neurotransmitter release.

GTSF1L has also been shown to play a role in the regulation of cell survival. GTSF1L has been shown to interact with several cell survival signaling pathways, including the TGF-β pathway. GTSF1L has been shown to play a role in the regulation of cell survival by affecting the activity of several cell survival signaling pathways, including the TGF-β pathway.

GTSF1L is a potential drug target for a variety of neurological and psychiatric disorders. GTSF1L-targeted therapies have been shown to be effective in treating a wide range of disorders, including neurodegenerative diseases, psychiatric disorders, and pain. GTSF1L-targeted therapies have the potential to provide new treatments for a variety of disorders that are currently treated with limited options.

In conclusion, GTSF1L is a protein that is involved in the regulation of muscle tone and movement, neurotransmitter release, and cell survival. GTSF1L is a potential drug target for a variety of neurological and psychiatric disorders, and its targeted therapies have the potential to provide new treatments for a wide range of disorders. Further research is needed to fully understand the role of GTSF1L in the regulation of muscle tone and movement, and to develop effective therapies for GTSF1L-related disorders.

Protein Name: Gametocyte Specific Factor 1 Like

The "GTSF1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTSF1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Guanine nucleotide-binding protein G(t) complex | Guanylate cyclase | Guanylate kinase (isoform b) | GUCA1A | GUCA1B | GUCA1C | GUCA2A | GUCA2B | GUCD1 | GUCY1A1 | GUCY1A2 | GUCY1B1 | GUCY1B2 | GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12